No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic

Abstract The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing, antibodies to the new species in humans is unclear. The ques...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2020-12, Vol.222 (12), p.1960-1964
Main Authors: Schwaiger, Julia, Karbiener, Michael, Aberham, Claudia, Farcet, Maria R, Kreil, Thomas R
Format: Article
Language:English
Subjects:
Antibodies, Neutralizing - immunology
Antibodies, Viral - immunology
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - virology
Cross Reactions
Disease transmission
Europe
Humans
Immunoglobulins
Immunoglobulins, Intravenous - immunology
Intravenous administration
Major and Brief Reports
Neutralization Tests
New species
Pandemics
Plasma - immunology
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing, antibodies to the new species in humans is unclear. The question is particularly relevant for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 intravenous immunoglobulin preparations, produced from plasma collected in Europe and the United States, confirmed highly potent neutralization of a seasonal coronavirus; however, no cross-neutralization of the new SARS-CoV-2 was seen.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiaa593